You’ll be able to find Tirz dirt cheap here. It’s the current “hot” GLP prescribed off label for Type 1 diabetics
Eli Lily is entering phase 3 trials with thousands of T1D subject to get FDA approval, but based on getting through phase 2 trials, and all the doctors prescribing it off label, it’s a very good indicator it’s safe and effective.
I don’t know much about Type I, but I know GLP use has to be carefully managed to keep insulin dose appropriate. It’s not as simple as with T2D and non-diabetics.
The main barrier at this point since FDA approval isn’t final, but a near certainty, isnt whether it’s safe and effective for T1D, its cost. Without FDA approval insurance won’t pay.
If I were in your position, I’d approach my doctor and say “I know Tirzapetide is being used in T1D off label very successfully, even though the final trials for FDA approval aren’t complete. I’m willing to self pay for it. Can you give me a prescription, I’d like to try it.
Then you can buy it very inexpensively from a source here, Your doctor won’t know you didn’t fill the prescription, but will be able to properly monitor and manage your use so you do it safely. *do not mention you’re using grey market Tirz to your doc if you go this route*
(Alternatively you can just buy Zepbound at the new $199 / mo self pay option Eli Lily is offering for legit pharma pens if that’s within your budget.)
Pharma or UGL, despite having to get your doctor on board, I assure you it’s worth it. These are life altering (in a positive way) compounds you won’t regret starting, especially in your case. You carry a lot more comorbidotied as a T1D, but GLPs can put you on the road so that with some careful choices (TRT, lipid & BP meds, possibly rHGH), all the risks that impact long term health and longevity (cardiovascular, metabolic) can be brought equal to, or even lower than your non T1D peers. Until recently, that would’ve been impossible.
Good luck.
Treatment with tirzepatide significantly reduces bodyweight and insulin dose versus placebo in people with type 1 diabetes and obesity, suggests the TIRTLE1 trial.
www.springermedicine.com